Browse the evidence

GIP promotes lipogenesis (fat storage) in adipose tissue, while GLP-1 promotes lipolysis (fat breakdown) indirectly via sympathetic nervous system activation.

GIP helps store fat in adipose tissue, while GLP-1 helps break it down. Dual agonists balance these effects to improve overall metabolic health.

Approximately two-thirds of the variability in Body Mass Index (BMI) among individuals within the same population is attributable to genetic factors rather than environmental differences.

Your body weight is heavily influenced by your genetics (about 67% of the variation). This means standard 'eat less, move more' advice may be less effective for you than for others because your biology fights back. Focus on environmental changes (like access to healthy food) and targeted therapies rather than just blaming yourself for lack of willpower.

Acute post-exercise elevations in growth hormone (GH) and cortisol are weakly correlated with gains in muscle fiber cross-sectional area (hypertrophy) but show no association with strength gains.

Do not design your workout based on the hope of a massive hormonal spike. The acute rise in testosterone or growth hormone after a set does not predict how much muscle you will gain. Focus on progressive overload and consistent training volume instead. The 'pump' or feeling of hormonal surge is not a reliable indicator of effective hypertrophy stimulus.

Insulin resistance in obesity causes a decreased thermic effect of glucose by limiting the rate of glucose uptake and storage, rather than by an intrinsic defect in thermogenic efficiency.

If you are obese, your body may not burn as many calories from a meal as a lean person's because insulin resistance slows down how fast your body stores glucose. This isn't a permanent defect; it's a rate-limiting step. Improving your insulin sensitivity (through exercise, weight loss, or diet) can help normalize how your body handles energy from food.

Menstrual cycle phase does not appreciably influence acute strength performance or chronic adaptations (strength/hypertrophy) to resistance exercise training in naturally cycling women.

Do not restrict your training volume, intensity, or frequency based on your menstrual cycle phase. The current scientific consensus indicates that hormonal fluctuations across the cycle do not significantly impact your ability to build strength or muscle. Focus on consistent, high-quality resistance training regardless of where you are in your cycle. If you experience menstrual symptoms that affect your well-being, adjust for comfort, not for perceived biological incapacity.

A Body Shape Index (ABSI) is a stronger predictor of all-cause mortality than BMI, waist circumference, waist-to-height ratio, or waist-to-hip ratio, with higher ABSI correlating to increased death rates.

Use the Body Shape Index (ABSI) instead of just BMI or waist circumference to assess your long-term mortality risk. ABSI is calculated using your height, weight, and waist circumference. A higher ABSI indicates a higher risk of death, independent of your BMI. While more complex to calculate than BMI, it offers a more accurate prediction of health outcomes by specifically targeting abdominal obesity relative to body size.

ABSI remains a consistent predictor of mortality hazard over long-term follow-up (at least 20 years), whereas the predictive power of other metrics may not be as persistent.

ABSI is a reliable long-term predictor of mortality risk, remaining significant for at least 20 years after measurement. This makes it a valuable tool for long-term health assessment, unlike some other metrics that may lose predictive power over time.

Food Balance Sheets (FBS) and household surveys systematically overestimate true individual nutrient intake due to waste, processing losses, and non-consumption allocation, making supply data a theoretical upper bound rather than a consumption measure.

When evaluating global nutrition reports, remember that 'supply' is the maximum possible intake, not what people actually eat. In developing nations, actual nutrient intake is likely lower than reported supply data suggests due to waste and processing losses.

Weight stigma and discrimination are significant behavioral and emotional mechanisms linking high body weight to psychological distress.

Recognize that weight stigma is a real and harmful social force, not a personal failing. Seek supportive environments and mental health resources that address the impact of discrimination.

Systemic inflammation and HPA-axis dysregulation are biological mechanisms mediating the link between high body weight and psychological distress.

Understand that biological factors like inflammation and stress hormone dysregulation contribute to the link between obesity and depression. This is not just 'in your head' but has a physical basis.

Individuals with Medicare, dual-eligible insurance, lower education, older age, and male sex bear the highest annual diet-related CMD costs.

Targeted interventions for older adults, men, those with lower education, and those with public insurance (Medicare/dual-eligible) could yield significant cost savings. Focus on increasing nuts, seeds, and seafood omega-3s, and reducing processed meats, sodium, and SSBs.

High dietary dissimilarity (variety of food attributes) is associated with greater gain in waist circumference and does not reduce the risk of type 2 diabetes, refuting the notion that 'eating everything in moderation' improves metabolic health.

Do not assume that eating a wide variety of foods is automatically healthy. If your 'variety' includes many processed, high-sodium, or high-sugar foods, it may lead to abdominal fat gain and higher diabetes risk. Focus on the quality of the foods you eat, not just the number of different types. High dietary dissimilarity (eating many different types of foods with different attributes) was linked to worse metabolic outcomes in this study.

Global sugar-sweetened beverage (SSB) intake among adults increased by 16% (0.37 servings/week) between 1990 and 2018, with the most dramatic increases occurring in Sub-Saharan Africa (+81.9%) and specific high-population countries like Nigeria and Ethiopia.

Track your weekly SSB servings. If you live in or travel to regions with rapidly rising intake (like Sub-Saharan Africa or parts of Asia), be aware that marketing is aggressively targeting these demographics. Aim to keep added sugars <5-10% of daily calories as recommended by national guidelines.

High-fat diets (>46% calories from fat, <21% from carbs) do not improve exercise performance despite increasing fat oxidation.

Do not follow a high-fat, low-carb diet to improve performance. While it may help your body burn more fat, it does not make you faster and can actually hurt your performance, especially in intense or long events.

Bariatric surgery induces early, pronounced improvements in hepatic and peripheral insulin sensitivity and glycemic control that occur independently of significant weight loss, primarily through anatomical remodeling of the gastrointestinal tract.

If you have severe obesity and type 2 diabetes, bariatric surgery can resolve your diabetes through hormonal changes in your gut, not just by making you smaller. This happens quickly, often before you lose much weight. Consult a multidisciplinary unit to see if you are a candidate.

GLP-1 receptor agonists (specifically liraglutide and dulaglutide) are associated with a statistically significant increase in the risk of overall thyroid disorders compared to placebo or other interventions, although they do not significantly increase the risk of specific conditions like thyroid cancer, hyperthyroidism, or hypothyroidism.

If you are taking a GLP-1 medication like liraglutide or dulaglutide, be aware that there is a slightly higher statistical risk of developing 'overall thyroid disorders' compared to those not taking the drug. However, this does not appear to increase your risk of thyroid cancer or major thyroid dysfunction. Standard monitoring is advised, but the fear of cancer based on animal studies is not supported by large human clinical trials.

Among specific GLP-1 receptor agonists, liraglutide and dulaglutide show a statistically significant increase in the risk of overall thyroid disorders, whereas semaglutide, lixisenatide, and exenatide do not show a significant effect.

Not all GLP-1 medications affect the thyroid equally. If you are concerned about thyroid health, liraglutide and dulaglutide have shown a statistically significant increase in overall thyroid disorders in large trials, whereas semaglutide, lixisenatide, and exenatide have not shown this significant risk. Discuss these differences with your provider when choosing a specific agent.

Tirzepatide requires GIP receptor (GIPR) activation to stimulate insulin secretion in human islets, as blocking GIPR consistently reduces this response.

Tirzepatide's effectiveness in lowering blood sugar relies on its ability to activate the GIP receptor, not just the GLP-1 receptor. In human tissue, blocking the GIP receptor stops tirzepatide from stimulating insulin, proving this second pathway is essential for its full benefit.

Tirzepatide stimulates glucagon secretion in human islets primarily through GIP receptor activation, which overrides the glucagon-suppressing effect of GLP-1 receptor activation.

Tirzepatide increases glucagon secretion via the GIP receptor, which might seem counterintuitive for a diabetes drug. However, this is a normal physiological response to nutrient sensing, and the drug's overall effect is still a significant reduction in blood glucose due to its powerful insulin-stimulating effects.

Tirzepatide stimulates insulin secretion in mouse islets predominantly through the GLP-1 receptor, with minimal GIP receptor contribution at therapeutic doses.

Research on tirzepatide using mice may not fully reflect how it works in humans, as mice require much higher doses for GIP receptor activation. This highlights the importance of human-specific studies for understanding the drug's full mechanism.

Intensive lifestyle intervention does not significantly improve objective physical examination measures of diabetic peripheral neuropathy (such as vibration sense or monofilament light touch) compared to control, except for a slight preservation of light touch sensation when both feet are considered together.

While lifestyle changes improve how patients *feel* (less pain, numbness), they may not always reverse objective nerve damage detectable by standard physical exams like monofilament testing. This highlights the importance of symptom management and prevention of progression, even if structural reversal is not achieved.

Unilateral immobilization or unloading causes profound muscle atrophy and metabolic risk factors in the immobilized limb, but these adaptations are specific to that limb and do not transfer to the non-immobilized control limb.

If you have to immobilize one limb (e.g., in a cast), expect that specific limb to lose muscle mass and strength, but know that your other limb will remain healthy and strong. This local specificity means you can maintain overall body function and use the healthy limb to support yourself without risking systemic decline.

Treatment with GLP-1 receptor agonists (specifically Liraglutide and Semaglutide) is associated with a significantly increased risk of developing psychiatric disorders, including major depression, anxiety, and suicidal behavior, in patients with obesity.

If you are taking or considering GLP-1 medications like Ozempic or Wegovy for obesity, be aware that studies link these drugs to a higher risk of depression, anxiety, and suicidal thoughts, especially with long-term use. Discuss your mental health history with your doctor before starting, and monitor your mood closely. If you experience worsening depression or suicidal thoughts, contact your healthcare provider immediately.

Adding a Very Low-Calorie Diet (VLCD) to a Weight-Management Programme (WMP) is not cost-effective compared to a WMP alone, despite producing greater short-term weight loss.

For those with severe obesity, adding a Very Low-Calorie Diet to a standard weight management program provides more weight loss in the first year but is not considered cost-effective. Standard WMPs are a more economically sound approach.